Life sciences industry trends 2025 check in

Baker Tilly's outlook on what lies ahead for industry leaders

As we enter into the second half of 2025, the life sciences industry continues to experience rapid transformation. Shifting political priorities in a presidential election year, heightened regulatory activity and growing geopolitical tensions have added new layers of complexity to an already challenging environment. Tariff fluctuations, changes to global trade agreements and evolving healthcare policies are placing additional strain on cross-border operations, supply chains, and pricing strategies. In parallel, the NIH’s ongoing funding priorities and research directives are influencing innovation pipelines, while activity in Washington, D.C., including proposed legislation around drug pricing, transparency, and healthcare access, is shaping the future policy landscape for the industry.

Meanwhile, increasing scrutiny around drug pricing and reimbursement models, coupled with the need for more transparent HCP engagement, continues to reshape industry practices. Organizations are also under pressure to manage changing tax regulations, updated governance requirements and ongoing global compliance standards—all while driving innovation and long-term growth.

Join Baker Tilly for a mid-year check-in on the life sciences industry with our leaders, where we will reflect on key developments from the first half of the year and assess the trends shaping the remainder of 2025 and beyond, such as:

Capital markets: The state of funding for emerging companies and the realities of scaling in a competitive environment
Regulatory outlook: Updates on drug pricing transparency, gross-to-net dynamics and policy shifts tied to election-year agendas
HCP engagement: Why simplification, standardization and compliance are more critical than ever
Technology and risk: Leveraging tech to manage regulatory exposure and streamline operations
Evidence generation: Demonstrating value throughout the product lifecycle to align with payer expectations
Strategic response: Turning risk into opportunity amid rapid industry change

This mid-year session is designed to equip life sciences leaders with timely insights, actionable takeaways and the strategic foresight needed to adapt and thrive in a highly dynamic environment.